Close

UPDATE: Citi Starts Amarin (AMRN) at Buy; Sees Favorable Risk/Reward Even if 'Going Alone' on Vascepa

Go back to UPDATE: Citi Starts Amarin (AMRN) at Buy; Sees Favorable Risk/Reward Even if 'Going Alone' on Vascepa

Amarin Corp (AMRN) Receives U.S. Patent Covering Vascepa

November 27, 2012 7:31 AM EST

Amarin Corp Plc (NASDAQ: AMRN) that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa® (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 13/282,145. On September 4, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this... More

Wedbush Comments on Amarin's (AMRN) Latest MARINE Family Notice of Allowance

November 26, 2012 1:04 PM EST

Wedbush commented on Amarin Corporation (NASDAQ: AMRN) Monday afternoon in light of another Notice of Allowance to MARINE-family applications.

The firm notes today's '247 application is part of the MARINE methods-of-use family and claims the use of Vascepa without specifying use of other lipid lowering agents, such as statins. The '247 application appears to be closely related to the 775 application (13/608,775) for which Amarin announced... More

Amarin (AMRN) Announces Notification of Patent Allowance for U.S. Application

November 26, 2012 7:34 AM EST

Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/610,247. This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.

The... More